Provides selected clinical trials currently open in pediatric neuro-oncology that utilize immunotherapy strategies within the categories of Vaccine therapy, Chimeric antigen receptor (CAR) T cell therapy, Checkpoint blockade, and Viral therapies. This table provides Immunotherapy category, Clinicaltrials.gov NCT number, Primary site location, Name of specific therapy, and Eligible disease types.

Table 1: Provides selected clinical trials currently open in pediatric neuro-oncology that utilize immunotherapy strategies within the categories of Vaccine therapy, Chimeric antigen receptor (CAR) T cell therapy, Checkpoint blockade, and Viral therapies. This table provides Immunotherapy category, Clinicaltrials.gov NCT number, Primary site location, Name of specific therapy, and Eligible disease types.

Recent clinical trials: Immunotherapy for pediatric brain tumors
Type of immunotherapy	Clinical trials.gov identifier	Lead institution/Consortium	Investigational agent	Eligible tumor type
Vaccine	NCT02960230	University of california, San francisco (PNOC)	H3.3K27M peptide vaccine	HLA-A201+ children with newly diagnosed DIPG and H3.3K27M positive glioma
	NCT01130077	University of pittsburgh	Glioma-associated antigen vaccine (EphA2, IL-13Rα2, survivin)	HLA-A2+ children with DIPG or recurrent or High grade glioma
	NCT01808820	University of miami (HGG Immuno Group)	Tumor lysate pulsed dendritic cell vaccine + Imiquimod	High grade glioma
	NCT02722512	Lurie children's hospital of chicago	Heat shock protein peptide complex-96 (HSPPC-96) vaccine	Newly diagnosed or Recurrent high grade glioma
	NCT03068832	Washington university	Neo-epitope personalized synthetic long peptide vaccine	Recurrent malignant CNS tumors
CAR T cell	NCT03500991	Seattle children's hospital	HER2-specific CAR T cell	HER2-positiive recurrent or Refractory CNS tumors
	NCT02208362	City of hope medical center	IL13Rα2-specific CAR T cell	Recurrent or Refractory high grade glioma
Checkpoint blockade	NCT02502708	Children's healthcare of Atlanta	IDO pathway inhibitor plus indoximod and Temozolomide	Progressive malignant brain tumors (including DIPG)
	NCT02359565	National cancer institute/Children's national medical center (PBTC)	Pembrolizumab	Recurrent, refractory high grade glioma, DIPG, Hypermutated tumors, Ependymoma, Medulloblastoma
	NCT02992964	The hospital for Sick children	Nivolumab	Hypermutant tumors
	NCT03130959	Bristol meyers squibb	Nivolumab, Ipilimumab	High grade CNS malignancies
Viral gene therapy	NCT00634231	Dana farber cancer institute	ADV-tk + Prodrug therapy in combination with radiation	Malignant glioma (WHO grade III or IV); Recurrent ependymoma
	NCT03330197	Ziopharm	Ad-RTS-hIL-12 + Veledimex	DIPG and Recurrent malignant brain tumors
Viral targets	NCT03299309	Duke university	PEP-CMV vaccine (human pp65 and CMV glyocoprotein B + KLH)	Recurrent medulloblastoma and Malignant glioma
Oncolytic virus	NCT02962167	University of california, San francisco (PNOC)	Modified measles vaccine (MV-NIS)	Recurrent medulloblastoma or ATRT
	NCT03178032	Clinica universidad de navarra	DNX-2401 oncolytic virus targeting abnormal RB pathway	DIPG